TokenPost·
Merck Says Efinopegdutide Meets Phase 2b MASH Trial Goal
The MK-6024-013 trial evaluated once-weekly subcutaneous efinopegdutide at 4 mg, 7 mg and 10 mg in adults with MASH and stage F2 or F3 liver fibrosis.
More news
- The BlockForward Industries grows SOL treasury to 8.7 million as token hits nearly three-month low
- TokenPostCNH Raises 2026 Industrial Free Cash Flow Outlook to $300 Million-$450 Million
- Bitcoin.com NewsBitcoin Could Rally Before Rate Cuts Begin, Binance Research Says
- UnchainedBinance Freezes Out MEXC Four Weeks Before U.S. Transfer Ban Applies
- Crypto BriefingCoreWeave posts $4B revenue, faces $47B debt and $1B interest expenses
- TokenPostRoss Introduces Tacit Chain for Private TAC Payments on Ethereum